for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Brickell Biotech Inc

BBI.N

Latest Trade

2.17USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.61

 - 

4.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.17
Open
--
Volume
--
3M AVG Volume
6.86
Today's High
--
Today's Low
--
52 Week High
4.55
52 Week Low
0.61
Shares Out (MIL)
7.81
Market Cap (MIL)
17.18
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Brickell Bio Announces Third Quarter Results

Brickell Biotech Says Filed Motion To Dismiss Complaint Filed By Bodor Labs In Federal Court

Vical Stockholders Approve Reverse Stock Split And Merger With Brickell

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Brickell Biotech Inc

Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.

Industry

Biotechnology & Drugs

Contact Info

5777 Central Ave Ste 102

+1.720.5054755

http://www.vical.com/

Executive Leadership

Reginald L. Hardy

Chairman of the Board, Co-Founder

Robert B. Brown

Chief Executive Officer, Director

Andrew D. Sklawer

Co-Founder, Chief Operating Officer, Secretary

R. Michael Carruthers

Chief Financial Officer

Jose Breton

Chief Accounting Officer, Controller

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
100.49
Price To Book (MRQ)
0.17
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-25.49
Return on Equity (TTM)
-24.38

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up